{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:30:39Z","timestamp":1767598239702,"version":"3.40.5"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Lenvatinib mesylate (LEN) is an orally administered tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). LEN therapy for HCC is associated with a high incidence of adverse events, including hypertension (HTN). However, the risk factors associated with LEN therapy remain unclear. This study investigated the incidence of LEN\u2010induced HTN (LENiHTN), and the relationship between HTN incidence and patient demographics in patients with HCC receiving LEN therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single\u2010centre, retrospective study of patients with HCC who received LEN therapy between 19 April 2018 and 30 September 2020. The observation period was from 1\u00a0week before the start to 1\u00a0month after the end of LEN administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy\u2010five patients with HCC were enrolled. Any grade LENiHTN was found in 74.7% of patients. Among patients with LENiHTN, the use of 2 or more antihypertensive agents before starting LEN was less common (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.007); serum potassium (K) and albumin\u2013bilirubin score (ALBI) were lower (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.013 and 0.038, respectively); and albumin (Alb) was higher (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.025). The cut\u2010off values of K, Alb and ALBI for HTN were estimated at 4.1\u00a0mEq\u2009L<jats:sup>\u22121<\/jats:sup>, 3.1\u00a0g dL<jats:sup>\u22121<\/jats:sup> and \u22121.736, respectively. In the multivariable analysis, low K (adjusted HR: 2.078) and low ALBI (adjusted HR: 2.845) were independent risk factors for LENiHTN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Low K, high Alb and low ALBI were independent risk factors for LENiHTN. Systematic evaluation of HTN risk and early intervention for HTN prevention among high\u2010risk patients can markedly enhance LEN therapy efficacy and use.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.16337","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T05:59:58Z","timestamp":1732168798000},"page":"894-902","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors for lenvatinib\u2010induced hypertension in patients with hepatocellular carcinoma: A retrospective study"],"prefix":"10.1111","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0993-6019","authenticated-orcid":false,"given":"Shusuke","family":"Uekusa","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences Toho University  Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misaki","family":"Nakashin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences Toho University  Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4606-7150","authenticated-orcid":false,"given":"Yuki","family":"Hanai","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences Toho University  Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences Toho University  Chiba Japan"},{"name":"Toho University Ohashi Medical Center  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Yanagino","sequence":"additional","affiliation":[{"name":"Toho University Omori Medical Center  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Arita","sequence":"additional","affiliation":[{"name":"Toho University Omori Medical Center  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Toho University Omori Medical Center  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritaka","family":"Wakui","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori) School of Medicine, Faculty of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenari","family":"Nagai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori) School of Medicine, Faculty of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Higai","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Biochemistry Faculty of Pharmaceutical Sciences Toho University  Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences Toho University  Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_10_2_1","DOI":"10.1200\/EDBK_200939"},{"doi-asserted-by":"publisher","key":"e_1_2_10_3_1","DOI":"10.1038\/s41575\u2010019\u20100186\u2010y"},{"doi-asserted-by":"publisher","key":"e_1_2_10_4_1","DOI":"10.1200\/JCO.2015.64.7412"},{"doi-asserted-by":"publisher","key":"e_1_2_10_5_1","DOI":"10.1016\/S0140\u20106736(18)30207\u20101"},{"doi-asserted-by":"publisher","key":"e_1_2_10_6_1","DOI":"10.1097\/HEP.0000000000000466"},{"doi-asserted-by":"publisher","key":"e_1_2_10_7_1","DOI":"10.1007\/s00535\u2010019\u201001642\u20101"},{"doi-asserted-by":"publisher","key":"e_1_2_10_8_1","DOI":"10.1159\/000531881"},{"doi-asserted-by":"publisher","key":"e_1_2_10_9_1","DOI":"10.1200\/JCO.2014.57.9151"},{"unstructured":"US Department of Health and Human Services [Internet]. Common terminology criteria for adverse events (CTCAE).https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf. Accessed April 1 2021.","key":"e_1_2_10_10_1"},{"unstructured":"R Core Team [Internet].R: A Language and Environment for Statistical Computing.https:\/\/www.R-project.org\/. Accessed April 1 2021.","key":"e_1_2_10_11_1"},{"doi-asserted-by":"publisher","key":"e_1_2_10_12_1","DOI":"10.1111\/bph.16180"},{"unstructured":"EISAI Inc. [Internet].The package insert of Lenvima\u00ae in Japan.https:\/\/medical.eisai.jp\/products\/?searchtext=%E3%83%AC%E3%83%B3%E3%83%93%E3%83%9E. Accessed April 1 2023.","key":"e_1_2_10_13_1"},{"doi-asserted-by":"publisher","key":"e_1_2_10_14_1","DOI":"10.1038\/ki.2011.288"},{"doi-asserted-by":"publisher","key":"e_1_2_10_15_1","DOI":"10.1152\/ajpheart.1998.274.3.H1054"},{"doi-asserted-by":"publisher","key":"e_1_2_10_16_1","DOI":"10.1016\/j.atherosclerosis.2017.03.039"},{"doi-asserted-by":"publisher","key":"e_1_2_10_17_1","DOI":"10.1200\/JCO.2005.05.098"},{"doi-asserted-by":"publisher","key":"e_1_2_10_18_1","DOI":"10.1074\/jbc.C300012200"},{"doi-asserted-by":"publisher","key":"e_1_2_10_19_1","DOI":"10.1172\/JCI17423"},{"doi-asserted-by":"publisher","key":"e_1_2_10_20_1","DOI":"10.1097\/HJH.0b013e32834786f0"},{"doi-asserted-by":"publisher","key":"e_1_2_10_21_1","DOI":"10.3390\/cancers12071867"},{"doi-asserted-by":"publisher","key":"e_1_2_10_22_1","DOI":"10.1002\/cam4.2241"},{"doi-asserted-by":"publisher","key":"e_1_2_10_23_1","DOI":"10.1136\/bmj.f1378"},{"doi-asserted-by":"publisher","key":"e_1_2_10_24_1","DOI":"10.1001\/jama.1997.03540440058033"},{"doi-asserted-by":"publisher","key":"e_1_2_10_25_1","DOI":"10.1016\/j.cmet.2014.12.006"},{"doi-asserted-by":"publisher","key":"e_1_2_10_26_1","DOI":"10.1152\/physiol.00022.2016"},{"doi-asserted-by":"publisher","key":"e_1_2_10_27_1","DOI":"10.11909\/j.issn.1671\u20105411.2015.02.009"},{"doi-asserted-by":"publisher","key":"e_1_2_10_28_1","DOI":"10.1016\/s0895\u20107061(01)02293\u20102"},{"doi-asserted-by":"publisher","key":"e_1_2_10_29_1","DOI":"10.1016\/j.atherosclerosis.2021.12.006"},{"doi-asserted-by":"publisher","key":"e_1_2_10_30_1","DOI":"10.1136\/bmjopen\u20102016\u2010011716"},{"doi-asserted-by":"publisher","key":"e_1_2_10_31_1","DOI":"10.1093\/advances\/nmaa041"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:18:58Z","timestamp":1741767538000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/bcp.16337"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16337","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2024,11,20]]}}}